JNJ 89853413
Alternative Names: JNJ-89853413Latest Information Update: 08 Nov 2024
Price :
$50 *
At a glance
- Originator Janssen Research & Development
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 01 Oct 2024 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route) prior to October 2024
- 01 Oct 2024 Preclinical trials in Myelodysplastic syndromes in USA (unspecified route) prior to October 2024
- 01 Oct 2024 Janssen Research & Development plans a phase I trial for Acute myeloid leukemia or Myelodysplastic neoplasms (Second-line therapy or greater) (NCT06618001)